Newswise – CLEVELAND –University Hospitals (UH) Brain Health and Memory Center. is now treating patients with LEQEMBI® (lecanemab), a Food and Drug Administration-approved drug for the treatment of Alzheimer’s disease.

“People with Alzheimer’s disease often have an abnormal buildup of plaques in their brain that contain a protein called beta-amyloid,” he said Charles J. Duffy, MD, PhD, Neurologist and director of the Brain Health & Memory Center at the UH Neurological Institute. “Lecanemab is an intravenous drug that targets and removes these plaques. It has the potential to slow cognitive and functional decline when used in the early stages of the disease. We are pleased to offer this groundbreaking treatment to our patients at UH.”

Lecanemab is given as an intravenous infusion every two weeks, with each session lasting about an hour. The infusions take place for one year with a total of 26 treatments. Patients are monitored for a period of time after each infusion to ensure there are no adverse reactions to the medication.

“This new drug has shown promise in clinical trials and could be a treatment option for patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease. Although there is currently no cure for Alzheimer’s, lecanemab can slow the progression of the disease, improve patients’ ability to participate in daily life and enable them to live independently for longer periods of time,” explained Dr. Duffy, who also holds the Alzheimer’s Disease A. William and Joanne Reynolds Chair in Brain Health at UH, is a professor at Case Western Reserve University School of Medicine.

People with symptoms of early Alzheimer’s disease and the confirmed presence of beta-amyloid plaques in the brain may be eligible for treatment with lecanemab. Early symptoms of Alzheimer’s may include: mild cognitive impairment such as forgetfulness and confusion, and mild dementia such as difficulty performing familiar tasks. The therapy has not been tested in people with advanced Alzheimer’s disease or those without clinical symptoms.

Although there is no single diagnostic test to confirm Alzheimer’s disease, doctors can use several approaches to make a diagnosis and determine whether treatment with lecanemab may be appropriate. Tests and procedures may include: Comprehensive personal and family medical history; mental status tests; physical and neurological examinations; blood tests; Spinal puncture to obtain a sample of cerebrospinal fluid for testing; MRI of the brain; and PET scan of the brain to look for beta-amyloid plaques.

Patients approved for lecanemab therapy will be carefully monitored at scheduled intervals determined by their doctor. Brain MRIs and laboratory tests are then performed at regular intervals to monitor side effects of the treatment.

To learn more about this treatment visit:


About University Hospitals / Cleveland, Ohio

Founded in 1866, University Hospitals serves patients’ needs through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and more than 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, Technion Israel Institute of Technology and the National Taiwan University College of Medicine affiliated. The main campus also includes UH Rainbow Babies & Children’s Hospital, one of the best children’s hospitals in the country; UH MacDonald Women’s Hospital, Ohio’s only women’s hospital; and the UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the country, with more than 3,000 ongoing clinical trials and research studies. UH Cleveland Medical Center consistently ranks among the top performers in national ranking surveys, including “America’s Best Hospitals” by U.S. News & World Report. UH is also home to 19 clinical care and research institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Keep following UH LinkedIn, Facebook And Twitter. For more information visit

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *